四環醫藥(00460.HK):軒竹生物1類創新藥獲批開展三期臨床試驗
四環醫藥(00460.HK)公布,旗下軒竹生物科技收到國家藥監局藥品審評中心通知,其在研1類創新藥「(口比)羅西尼」開展三期臨床試驗的申請獲得批准。
該臨床試驗中,(口比)羅西尼與氟維司群將聯合用於既往曾接受內分泌治療後出現疾病進展的激素受體陽性(HR+)/人類表皮生長因子受體2陰性(HER2-)局部晚期、復發或轉移性乳腺癌。
公司表示,軒竹生物已召開(口比)羅西尼三期臨床啟動會,將於近期開始臨床試驗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.